Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia’s Biota To Become U.S. Company Through Merger With Nabi

This article was originally published in PharmAsia News

Executive Summary

Biota and Nabi have proposed a merger that will give the Australian company access to the U.S. biotech market and increase its cash on hand.

You may also be interested in...



Daiichi Sankyo and Biota Bring Next-gen Flu Drug To Japan; Continue Search For Western Partner

TOKYO - Daiichi Sankyo has received marketing and manufacturing approval in Japan for its second-generation long-acting neuraminidase inhibitor Inavir (laninamivir), bringing encouraging news to Daiichi Sankyo and Australian partner Biota, which have faced delays in snagging an ex-Japan partner for the drug

UK Orders 10.6 Million Doses of GSK/Biota Relenza To Cope With Tamiflu-resistant Flu

PERTH, Australia - Melbourne-based Biota Holdings announced recently that partner GlaxoSmithKline has been awarded a contract by the UK Department of Health for 10.6 million treatment courses of flu drug Relenza (zanamivir). Relenza was developed by Biota and is marketed by GSK

IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic

Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132327

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel